Aduhelm, an anti-amyloid monoclonal antibody approved for Alzheimer's, failed to show meaningful clinical benefit despite targeting the amyloid hypothesis, suggesting that amyloid reduction alone is insufficient for cognitive protection.

factualpending

Speaker

Dr. David Perlmutter

Evidence Quote

“Aduhelm uh fiasco, where a drug was created that uh was designed to target beta amyloid and how that turned out not to be meaningful drug”

Source

Oral Bacteria And Your Health - with Dr. Mark Burhenne | The Empowering Neurologist EP. 162— DavidPerlmutterMD
Created: 8/12/2026, 6:27:27 PM

Your notes

Loading notes...